Oncotarget

Research Papers:

The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells

Francesco Morra, Francesco Merolla, Virginia Napolitano, Gennaro Ilardi, Caterina Miro, Simona Paladino, Stefania Staibano, Aniello Cerrato and Angela Celetti _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:31815-31829. https://doi.org/10.18632/oncotarget.16463

Metrics: PDF 1079 views  |   HTML 1988 views  |   ?  


Abstract

Francesco Morra1, Francesco Merolla2,3, Virginia Napolitano1,2, Gennaro Ilardi2, Caterina Miro1, Simona Paladino4, Stefania Staibano2, Aniello Cerrato1, Angela Celetti1

1Institute for Experimental Endocrinology and Oncology, Research National Council, Naples, Italy

2Department of Advanced Biomedical Sciences, University “Federico II”, Naples, Italy

3Department of Medicine and Health Sciences “V. Tiberio”, University of Molise, Campobasso, Italy

4Department of Molecular Medicine and Medical Biotechnology, University “Federico II”, Naples, Italy

Correspondence to:

Angela Celetti, email: celetti@unina.it

Keywords: CCDC6, USP7, ARFL and V7, P5091, olaparib

Received: December 08, 2016     Accepted: March 15, 2017     Published: March 22, 2017

ABSTRACT

Purpose of the study: Reduced levels of the tumor suppressor protein CCDC6 sensitize cancer cells to the treatment with PARP-inhibitors. The turnover of CCDC6 protein is regulated by the de-ubiquitinase USP7, which also controls the androgen receptor (AR) stability. Here, we correlated the expression levels of CCDC6 and USP7 proteins in primary prostate cancers (PC). Moreover, we tested the efficacy of the USP7 inhibitors, in combination with PARP-inhibitors as a novel therapeutic option in advanced prostate cancer.

Experimental techniques: PC cells were exposed to USP7 inhibitor, P5091, together with cycloheximide, to investigate the turnover of the USP7 substrates, AR and CCDC6. As outcome of the AR downregulation, transcription targets of AR and its variant V7 were examined by qPCR. As a result of CCDC6 degradation, the induction of PARP inhibitors sensitivity was evaluated by analyzing PC cells viability and foci formation. We scored and correlated CCDC6 and USP7 expression levels in a prostate cancer tissue microarray (TMA).

Results: P5091 accelerated the degradation of AR and V7 isoform affecting PSA, UBE2C, CDC20 transcription and PC cells proliferation. Moreover, P5091 accelerated the degradation of CCDC6 sensitizing the cells to PARP-inhibitors, that acted sinergistically with genotoxic agents. The immunohistochemical analysis of both CCDC6 and USP7 proteins exhibited significant correlation for the intensity of staining (p ≤ 0.05).

Data interpretation: Thus, CCDC6 and USP7 represent predictive markers for the combined treatment of the USP7-inhibitors and PARP-inhibitors in advanced prostate cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 16463